Suppr超能文献

对阿普米司特治疗有反应的难治性皮肤性皮肌炎伴严重头皮瘙痒

Refractory Cutaneous Dermatomyositis With Severe Scalp Pruritus Responsive to Apremilast.

出版信息

J Clin Rheumatol. 2021 Dec 1;27(8S):S561-S562. doi: 10.1097/RHU.0000000000000999.

Abstract

Dermatomyositis (DM) is a subset of idiopathic inflammatory myopathy with characteristic cutaneous manifestations and muscle weakness. Conventional treatments for DM include glucocorticoids and other immunosuppressive or immunomodulatory agents including hydroxychloroquine, methotrexate, azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine, and intravenous immunoglobulin. Refractory patients require more aggressive or novel therapies. Apremilast has not been studied for the management of refractory cutaneous DM. We report a case of a patient with refractory DM with severe scalp pruritus treated with apremilast who demonstrated significant improvement in her skin disease and complete resolution of scalp pruritus.

摘要

皮肌炎(DM)是特发性炎症性肌病的一个亚类,具有特征性的皮肤表现和肌肉无力。DM 的常规治疗包括糖皮质激素和其他免疫抑制剂或免疫调节剂,包括羟氯喹、甲氨蝶呤、硫唑嘌呤、霉酚酸酯、他克莫司、环孢素和静脉注射免疫球蛋白。难治性患者需要更积极或新的治疗方法。阿普米司特尚未被研究用于治疗难治性皮肤 DM。我们报告了一例难治性 DM 伴严重头皮瘙痒的患者,接受阿普米司特治疗后,其皮肤病显著改善,头皮瘙痒完全缓解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验